Evidence map›Paper›PMID 28634400›Full record

ArticleScientific reports2017

Chronic treatment with cisplatin induces chemoresistance through the TIP60-mediated Fanconi anemia and homologous recombination repair pathways.

Wen-Pin Su, Yen-Chih Ho, Cheng-Kuei Wu, Sen-Huei Hsu, Jia-Lin Shiu, Jheng-Cheng Huang, Song-Bin Chang, Wen-Tai Chiu, Jan-Jong Hung, Tsung-Lin Liu and 5 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Tip60: updates.Journal of applied genetics · 2018
    Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Wen-Pin SuInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, No.35, Xiaodong Road, Tainan 704, Taiwan. wpsu@mail.ncku.edu.tw.
Yen-Chih HoDepartment of Life Sciences, National Cheng Kung University, No.1 University Road, Tainan, 701, Taiwan.
Cheng-Kuei WuInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, No.35, Xiaodong Road, Tainan 704, Taiwan.ORCID 0000-0002-4390-8209
Sen-Huei HsuDepartment of Life Sciences, National Cheng Kung University, No.1 University Road, Tainan, 701, Taiwan.
Jia-Lin ShiuDepartment of Life Sciences, National Cheng Kung University, No.1 University Road, Tainan, 701, Taiwan.
Jheng-Cheng HuangInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, No.35, Xiaodong Road, Tainan 704, Taiwan.
Song-Bin ChangDepartment of Life Sciences, National Cheng Kung University, No.1 University Road, Tainan, 701, Taiwan.
Wen-Tai ChiuDepartment of Biomedical Engineering, National Cheng Kung University, Tainan, 701, Taiwan.
Jan-Jong HungDepartment of Biotechnology and Bioindustry Science, National Cheng-Kung University, Tainan, 701, Taiwan.
Tsung-Lin LiuDepartment of Biotechnology and Bioindustry Science, National Cheng-Kung University, Tainan, 701, Taiwan.
Wei-Sheng WuDepartment of Electrical Engineering, National Cheng Kung University, Tainan, 701, Taiwan.
Pei-Yu WuInstitute of Biological Chemistry, Academia Sinica, Taipei, 11529, Taiwan.
Wu-Chou SuDepartment of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.
Jang-Yang ChangDepartment of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.
Hungjiun LiawDepartment of Life Sciences, National Cheng Kung University, No.1 University Road, Tainan, 701, Taiwan. liawh@mail.ncku.edu.tw.ORCID 0000-0002-3481-709X
National Cheng Kung University · TWNational Cheng Kung University Hospital · TWInstitute of Biological Chemistry, Academia Sinica · TWNational Health Research Institutes · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Fanconi anemia pathway in coordination with homologous recombination is essential to repair interstrand crosslinks (ICLs) caused by cisplatin. TIP60 belongs to the MYST family of acetyltransferases and is involved in DNA repair and regulation of gene transcription. Although the physical interaction between the TIP60 and FANCD2 proteins has been identified that is critical for ICL repair, it is still elusive whether TIP60 regulates the expression of FA and HR genes. In this study, we found that the chemoresistant nasopharyngeal carcinoma cells, derived from chronic treatment of cisplatin, show elevated expression of TIP60. Furthermore, TIP60 binds to the promoters of FANCD2 and BRCA1 by using the chromatin immunoprecipitation experiments and promote the expression of FANCD2 and BRCA1. Importantly, the depletion of TIP60 significantly reduces sister chromatid exchange, a measurement of HR efficiency. The similar results were also shown in the FNACD2-, and BRCA1-deficient cells. Additionally, these TIP60-deficient cells encounter more frequent stalled forks, as well as more DNA double-strand breaks resulting from the collapse of stalled forks. Taken together, our results suggest that TIP60 promotes the expression of FA and HR genes that are important for ICL repair and the chemoresistant phenotype under chronic treatment with cisplatin.

Indexed as

Recombinational DNA RepairAcetylationBiomarkersBRCA1 ProteinCell CycleCell LineCisplatinDNA Breaks, Double-StrandedDrug ResistanceFanconi AnemiaFanconi Anemia Complementation Group D2 ProteinGene Expression RegulationHistonesHomologous RecombinationHumansLysine Acetyltransferase 5BiomarkersBRCA1 ProteinBRCA1 protein, humanCisplatinFanconi Anemia Complementation Group D2 ProteinHistonesKAT5 protein, humanLysine Acetyltransferase 5RNA, Small Interfering

Identifiers

PMID28634400
PMCPMC5478611
OpenAlexW2701033580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.